research use only

Voglibose Carbohydrate Metabolism inhibitor

Name: Voglibose
Brand: Selleck Chemicals
SKU: S4101
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S4101

Voglibose (AO 128) is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.

Chemical Structure

Molecular Weight: 267.28

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S410101 DMSO]74 mg/mL]false]Water]74 mg/mL]false]Ethanol]Insoluble]false Purity: 100%

100

Related Targets	P450 (e.g. CYP17) Dehydrogenase PDE phosphatase PPAR HSP (HSP90) Vitamin Transferase Mitochondrial Metabolism Casein Kinase Serine/threonin kinase Lipoxygenase Phospholipase (e.g. PLA) Retinoid Receptor DPP ACE Peroxidases Amino Acids and Derivatives Fatty Acid Synthase FXR HMG-CoA Reductase Carbonic Anhydrase Lipase Decarboxylase DHFR IDO/TDO Hydroxylase PCSK9 OXPHOS ROR
Related Products	2-Deoxy-D-glucose (2-DG) Lonidamine Bromopyruvic acid (3-BP) LY2608204 1-Deoxynojirimycin Dorzagliatin 4',7-Dimethoxy-5-Hydroxyflavone BI-9787 Hexokinase 1 Antibody [F18A5] Eleutherol Kaempferol-3-O-neohesperidoside Nodakenetin DLST Antibody [K3H24] AZD1656 N-Caffeoyl O-methyltyramine GALT Antibody [C15E2] GAA Antibody [H21L6] PCK1 Antibody [P16P6] FBPase-1 inhibitor-1 Butyl isobutyl phthalate Andrographis Herba Extract GFPT2 Antibody [C1C22] AM2394 M6PR (cation dependent) Antibody [J4M13] PFKM + PFKL Antibody [K8F12] Viburnum Dilatatum Extract Hexokinase II Antibody [F23A5] Ketohexokinase inhibitor 1 WAY-297848 FBP1 Antibody [A7L2]

Chemical Information, Storage & Stability

Molecular Weight	267.28	Formula	C₁₀H₂₁NO₇	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	83480-29-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AO 128			Smiles	C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO

Solubility

In vitro
Batch:

DMSO : 74 mg/mL (276.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 74 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.7mg/ml (13.84mM)	Taking the 1 mL working solution as an example, add 50 μL of 74 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.375mg/ml (1.40mM)	Taking the 1 mL working solution as an example, add 50 μL of 7.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	α-glucosidases ^[1]
In vitro	Voglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The K_i values of this compound for sucrase and maltase are about 10⁶and 10⁵ times smaller than the K_m values for sucrose and maltose. ^[1]
In vivo	Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. This compound (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. It (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. ^[2] This chemical (0.001%) treatment increases GLP-1 secretion (this compound alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (this compound alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. It (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. This compound (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice. ^[3] It (0.001% and 0.005%) stimulates GLP-1 secretion in ob/ob mice, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. This chemical (0.001% and 0.005%) decreases plasma DPP-4 activity unexpectedly by 40% to 51% in ob/ob mice, resulting from reduced plasma DPP-4 concentrations. It (0.001% and 0.005%) increases GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively, in ob/ob mice. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/16457643/ [2] https://pubmed.ncbi.nlm.nih.gov/9145209/ [3] https://pubmed.ncbi.nlm.nih.gov/20151999/ [4] https://pubmed.ncbi.nlm.nih.gov/19208898/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01055652	Completed	Type 2 Diabetes Mellitus	AstraZeneca\|Bristol-Myers Squibb	January 2010	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):